|
Aug 11
|
Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update
|
|
Jul 28
|
Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025
|
|
Jul 25
|
Goldman Sachs Resumes Roivant Sciences (ROIV) Coverage with ‘Buy’ Rating
|
|
Jun 16
|
Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics
|
|
Feb 12
|
Roivant Sciences price target lowered to $12 from $13 at BofA
|
|
Feb 12
|
News Flash: Analysts Just Made A Captivating Upgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) Forecasts
|
|
Jan 29
|
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025
|